• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

VINBLASTINE Drug Record

  • Summary
  • Interactions
  • Claims
  • VINBLASTINE chembl:CHEMBL159 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    NSC-47842
    [3H]-VINBLASTINE
    VELBAN
    VINBLASTINE

    Drug Info:

    Drug Class antineoplastic agents
    Year of Approval 1965
    FDA Approval 1965
    Drug Class small molecule
    Drug Indications Antineoplastic Agents
    (3 More Sources)

    Publications:

    Zheng J et al., 2013, Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity., Eur J Med Chem
    Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett
    Nievergelt A et al., 2010, Identification of serotonin 5-HT1A receptor partial agonists in ginger., Bioorg Med Chem
    Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod
    Correia, 1991, Effects of antimitotic agents on tubulin-nucleotide interactions., Pharmacol. Ther.
    Gupta et al., 2003, Antimicrotubular drugs binding to vinca domain of tubulin., Mol. Cell. Biochem.
    Islam et al., 2004, Microtubulin binding sites as target for developing anticancer agents., Mini Rev Med Chem
    Jordan et al., 2007, How do microtubule-targeted drugs work? An overview., Curr Cancer Drug Targets
    Jordan et al., 1998, Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle., Med Res Rev
    Vogelzang et al., 1982, Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors., Cancer Res.
    Vacca et al., 1999, Antiangiogenesis is produced by nontoxic doses of vinblastine., Blood
    Bornmann et al., 1994, Analysis of drug transport kinetics in multidrug-resistant cells using a novel coumarin-vinblastine compound., Biochemistry
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Aglietta et al., 2000, Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease., Cancer
    Tishler et al., 1996, The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1., Br. J. Cancer Suppl.
    Seidman et al., 1992, Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer., J. Urol.
    Gröne et al., 1998, Regulation of parathyroid hormone-related protein expression in a canine squamous carcinoma cell line by colchicine., Exp. Toxicol. Pathol.
    Sheridan et al., 1996, Microtubules regulate pulmonary vascular smooth muscle contraction., J. Surg. Res.
    Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma
    Warberg et al., 1980, Ion-induced release of LHRH, TRH and alpha-MSH from hypothalamic synaptosomes and its inhibition by vinblastine., Pflugers Arch.
  • VINBLASTINE   PTHLH

    Interaction Score: 2.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9784008


    Sources:
    NCI

  • VINBLASTINE   CGA

    Interaction Score: 1.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6181870


    Sources:
    NCI

  • VINBLASTINE   TRH

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6774314


    Sources:
    NCI

  • VINBLASTINE   ABCB4

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7918493


    Sources:
    NCI

  • VINBLASTINE   TBXA2R

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8632653


    Sources:
    NCI

  • VINBLASTINE   TUBA1A

    Interaction Score: 0.39

    Interaction Types & Directionality:
    adduct

    Interaction Info:

    PMIDs:
    23708010 23916255 1818332 14619954 15579115 18220533 9664292


    Sources:
    DTC

  • VINBLASTINE   TUBB

    Interaction Score: 0.32

    Interaction Types & Directionality:
    adduct
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    23708010 23916255 1818332 14619954 15579115 18220533 9664292


    Sources:
    DTC

  • VINBLASTINE   TUBB4A

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBA3C

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBB2A

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    23708010 23916255


    Sources:
    DTC TdgClinicalTrial TEND

  • VINBLASTINE   KLK3

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1371564


    Sources:
    NCI

  • VINBLASTINE   CDKN1A

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8763853


    Sources:
    NCI

  • VINBLASTINE   GSTM1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23323945


    Sources:
    PharmGKB

  • VINBLASTINE   TUBB4B

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC TTD

  • VINBLASTINE   MMP2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10590059


    Sources:
    NCI

  • VINBLASTINE   TUBB8

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBA3E

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBA1B

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBA4A

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBB2B

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBB6

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBA3D

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBA1C

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBB3

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   TUBB1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23708010 23916255


    Sources:
    DTC

  • VINBLASTINE   CSF2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10640980


    Sources:
    NCI

  • VINBLASTINE   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20363635 21348461


    Sources:
    DTC

  • VINBLASTINE   NR1I2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • VINBLASTINE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528


    Sources:
    PharmGKB

  • VINBLASTINE   GMNN

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: VINBLASTINE

    • Version: 01-August-2011

    Alternate Names:
    VINBLASTINE Primary Drug Name

    Drug Info:
    Year of Approval 1965
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: VINBLASTINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antineoplastic Agents
    Drug Class small molecule
    FDA Approval 1965

    Publications:

  • NCI: VINBLASTINE

    • Version: 14-September-2017

    Alternate Names:
    C930 NCI drug code

    Drug Info:

    Publications:
    Bornmann et al., 1994, Analysis of drug transport kinetics in multidrug-resistant cells using a novel coumarin-vinblastine compound., Biochemistry
    Gorczyca et al., 1992, Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide., Cancer Res.
    Gröne et al., 1998, Regulation of parathyroid hormone-related protein expression in a canine squamous carcinoma cell line by colchicine., Exp. Toxicol. Pathol.

  • DTC: VINBLASTINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL159 ChEMBL Drug ID

    Drug Info:

    Publications:
    Zheng J et al., 2013, Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity., Eur J Med Chem
    Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett
    Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod

  • PharmGKB: vinblastine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma

  • TTD: Vinblastine

    • Version: 2020.06.01

    Alternate Names:
    D0W9MM TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL159

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21